EDGAR pro
by EDGAR Online

ESTRELLA IMMUNOPHARMA, INC.

Reported by

PUSSINEN CYNTHIA

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 11/04/26 for the Period Ending 11/02/26

Address	5858 HORTON STREET, SUITE 370 EMERYVILLE, CA, 94608
Telephone	(510) 318-9098
CIK	0001844417
Symbol	ESLA
SIC Code	2836 - Biological Products, (No Diagnostic Substances)
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
https://www.edgar-online.com
© Copyright 2026, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.

FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Pussinen Cynthia	**Estrella Immunopharma, Inc. [ESLA]**	
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	__X__ Director _____ 10% Owner
5858 HORTON ST, SUITE 370	**11/2/2026**	__X__ Officer (give title below) _____ Other (specify below)
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	**Chief Executive Officer**
EMERYVILLE CALIFORNIA 94608		6. Individual or Joint/Group Filing (Check Applicable Line)
(City) (State) (Zip/Postal Code)		_X_ Form filed by One Reporting Person
UNITED STATES		___ Form filed by More than One Reporting Person
(Country)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	**$0.43**	**11/2/2026**		**A** (2)		**1,000,000**		(1)	**11/2/2036**	**Common Stock**	**1,000,000**	**$0**	**1,000,000**	**D**	

Explanation of Responses:

(1) The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer through each vesting date.

(2) The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d).

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Pussinen Cynthia **5858 HORTON ST, SUITE 370** **EMERYVILLE** **CALIFORNIA** **94608** **UNITED STATES**	**X**		**Chief Executive Officer**	

Signatures

Cynthia Pussinen **11/4/2026**

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

* Form 4: SEC 1474 (03-26).